The combination of rifampin plus moxifloxacin is synergistic for suppression of resistance but antagonistic for cell kill of Mycobacterium tuberculosis as determined in a hollow-fiber infection model.
Moxifloxacin is under development for expanded use against Mycobacterium tuberculosis. Rifampin is a mainstay of therapy. We examined the interaction of moxifloxacin plus rifampin for log-phase and nonreplicating persister (NRP) organisms. For this evaluation, we employed our hollow-fiber infection model, in which organisms are exposed to clinically relevant drug concentration-time profiles and the impact on bacterial cell kill and resistant subpopulation amplification is determined. In log phase, resistance emergence was observed in all monotherapy regimens and in no combination therapy regimen. No difference was seen in time to a 3-log reduction in the bacterial burden; there was a significant difference in time to resistance emergence (P = 0.0006). In the NRP experiment, no resistance emergence was seen. There was a significant difference between the monotherapy and combination therapy regimens in time to a 3-log reduction in the bacterial burden (P = 0.042). The combination is efficacious for suppressing resistant organisms but is antagonistic for cell kill.
Drusano
G L
GL
Ordway Research Institute, Albany, New York, USA. gdrusano@ordwayresearch.org
Sgambati
Nicole
N
Eichas
Adam
A
Brown
David L
DL
Kulawy
Robert
R
Louie
Arnold
A
D000995:Antitubercular Agents / Q000494:pharmacology*; D001372:Aza Compounds / Q000494:pharmacology*; D004353:Drug Evaluation, Preclinical / Q000295:instrumentation; D024881:Drug Resistance, Bacterial; D004357:Drug Synergism; D024841:Fluoroquinolones; D006801:Humans; D050296:Microbial Viability / Q000187:drug effects*; D008954:Models, Biological; D000077266:Moxifloxacin; D009169:Mycobacterium tuberculosis / Q000187:drug effects* / Q000254:growth & development; D011804:Quinolines / Q000494:pharmacology*; D012293:Rifampin / Q000494:pharmacology*; D014376:Tuberculosis / Q000188:drug therapy* / Q000382:microbiology
D000995:Antitubercular Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D000077266:Moxifloxacin; D012293:Rifampin
Antimicrob Agents Chemother. 2009 Jun;53(6):2266-73
19289521
J Bacteriol. 2001 Sep;183(18):5311-6
11514514
Proc Natl Acad Sci U S A. 2008 Apr 22;105(16):6145-9
18427112
Antimicrob Agents Chemother. 2009 Oct;53(10):4178-84
19620331
Infect Immun. 1996 Jun;64(6):2062-9
8675308
J Bacteriol. 1996 Aug;178(15):4484-92
8755875
Lancet. 2009 Apr 4;373(9670):1183-9
19345831
Pharmacol Rev. 1995 Jun;47(2):331-85
7568331
Am Rev Respir Dis. 1977 Oct;116(4):627-35
411404
Am J Respir Crit Care Med. 2009 Aug 1;180(3):273-80
19406981
PLoS Med. 2008 Apr 1;5(4):e75
18384229
Bull World Health Organ. 1964;31:273-94
14253244
Antimicrob Agents Chemother. 1992 Mar;36(3):548-51
1622164
Tuber Lung Dis. 1998;79(2):127-32
10645451
J Antimicrob Chemother. 1985 Jan;15 Suppl A:125-30
3980323
Am J Respir Crit Care Med. 2003 Feb 15;167(4):603-62
12588714